Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
Completed · Phase 1 · Has a placebo group
Conditions studied: Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
In brief
A Phase 1, Partially Blind, Placebo Controlled, Randomized, Combined Single Ascending Dose (SAD) with a Food Effect Cohort (Part 1), Multiple Ascending Dose (MAD) (Part 2), and Relative Bioavailability (rBA) (Part 3) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBAJ-876 in Healthy Adult Subjects
Key facts
- Study ID
- NCT04493671
- Run by
- Global Alliance for TB Drug Development
- People needed
- 137
- Starts
- 2020-06-08
- Expected to finish
- 2022-11-15
- Last updated by the study team
- 2025-06-04
Who can join
Age: 19 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- Worldwide Clinical Trials — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.